Skip to main content
Account

Table 2 Tissue to plasma exposure ratio of paclitaxel for tumor, liver, and spleen following intravenous administration

From: Nanosuspension delivery of paclitaxel to xenograft mice can alter drug disposition and anti-tumor activity

Tissue to plasma ratio

Formulation

 

Cremophor EL:ethanol

Nanosuspension

Tumor AUC0-8/plasma AUC0-8

0.7

8.3

Liver AUC0-8/plasma AUC0-8

3.6

810.0

Spleen AUC0-8/plasma AUC0-8

1.1

16.8

  1. AUC0-8, area under the concentration-time profile from 0 to 8 h.

Navigation